You are currently viewing Three-Year Clinical Outcomes of SMART-STRATEGY-Randomized Trial

Three-Year Clinical Outcomes of SMART-STRATEGY-Randomized Trial

EBC - ON DEMAND

European Bifurcation Club 2015 – EBC 2015 – Athens, Greece

News (2)

Three-Year Clinical Outcomes of SMART-STRATEGY-Randomized Trial

Author: Joo-Yong Hahn, Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Korea

 

SMART-STRATEGY trial

  • Objective
    • To determine the optimal indications for SB ballooning and/or stenting in the provisional approach
  • Design
    • Prospective, randomized, open-label, single-center study comparing conservative vs. aggressive strategy for SB treatment

SUMMARY

  • At 3 years, conservative strategy was associated with a lower incidence of TVF mainly due to decreased risk of cardiac death or MI and TLR in the MV.
  • The clinical benefits of a conservative strategy for provisional SB intervention was remarkable between 1 year and 3 years in landmark analysis .
  • The conservative strategy might be considered as the preferred approach for provisional SB intervention.

 

Download here 

Leave a Reply